ADHD treatment and pregnancy

Drug Safety

Volumn 37, Issue 6, 2014, Pages 397-408

  Besag, Frank M C ^a  

^a SEPT: South Essex Partnership University NHS Foundation Trust ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE DERIVATIVE; ATOMOXETINE; DEXAMPHETAMINE; METHYLPHENIDATE;

ATTENTION DEFICIT DISORDER; BREAST FEEDING; BREAST MILK; DELIVERY; FETUS MALFORMATION; FOOD AND DRUG ADMINISTRATION; HUMAN; IMPULSIVENESS; LACTATION; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PREGNANCY; PRIORITY JOURNAL; REVIEW; UNPLANNED PREGNANCY; ANIMAL; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; FEMALE; UNITED STATES;

ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BREAST FEEDING; FEMALE; HUMANS; PREGNANCY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84901911944     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-014-0168-5     Document Type: Review

References (50)

1. Polanczyk G, de Lima M, Horta B, Biederman J, Rohde L. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164(6):942-8. (Pubitemid 46972911)
2. Faraone SV, Biederman J. What is the prevalence of adult ADHD? Results of a population screen of 966 adults. J Atten Disord. 2005;9(2):384-91. (Pubitemid 41608110)
3. Haervig KB, Mortensen LH, Hansen AV, Strandberg-Larsen K. Use of ADHD medication during pregnancy from 1999 to 2010: a Danish register-based study. Pharmacoepidemiol Drug Saf. 2014;23(5):526-33.
4. US Food and Drug Administration. Ritalin (FDA approval). US Food and Drug Administration (2014). http://www.accessdata.fda.gov/drugsatfda-docs/label/ 2013/010187s077lbl.pdf.
5. US Food and Drug Administration. Vyvanse (lisdexamfetamine) FDA approval. US Food and Drug Administration (2014). http://www.accessdata.fda.gov/ drugsatfda-docs/label/2013/021977s030lbl.pdf.
6. The National Institute for Health and Clinical Excellence. Diagnosis and management of ADHD in children, young people and adults: guidance.nice.org.uk/ cg72. The National Institute for Health and Clinical Excellence: NICE (2013). http://www.nice.org.uk/nicemedia/live/12061/42059/42059.pdf.
7. Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716-23. (Pubitemid 44464584)
8. CDC. Key findings: trends in the parent-report of health care provider-diagnosis and medication treatment for ADHD: United States, 2003-2011. CDC: Centers for Disease Control and Prevention (2013). http://www.cdc.gov/ ncbddd/adhd/features/key-findings-adhd72013.html.
9. CDC: Centers for Disease Control and Prevention. Births and natality (USA). CDC: Centers for Disease Control and Prevention (2011). http://www.cdc.gov/nchs/fastats/births.htm.
10. Faraone SV, Biederman J, Spencer T, Wilens T, Seidman LJ, Mick E, et al. Attention-deficit/hyperactivity disorder in adults: an overview. Biol Psychiatry. 2000;48(1):9-20. (Pubitemid 30407145)
11. Rosler M, Retz W, Retz-Junginger P, Hengesch G, Schneider M, Supprian T, et al. Prevalence of attention deficit-/hyperactivity disorder (ADHD) and comorbid disorders in young male prison inmates. Eur Arch Psychiatry Clin Neurosci. 2004;254(6):365-71. (Pubitemid 40192991)
12. Biederman J, Wilens T, Mick E, Milberger S, Spencer TJ, Faraone SV. Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): effects of ADHD and psychiatric comorbidity. Am J Psychiatry. 1995;152(11):1652-8.
13. Wilens TE, Faraone SV, Biederman J, Gunawardene S. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics. 2003;111(1):179-85. (Pubitemid 36071051)
14. Wilens TE. Impact of ADHD and its treatment on substance abuse in adults. J Clin Psychiatry. 2004;65:38-45.
15. Mick E, Biederman J, Faraone SV, Sayer J, Kleinman S. Case-control study of attention-deficit hyperactivity disorder and maternal smoking, alcohol use, and drug use during pregnancy. J Am Acad Child Adolesc Psychiatry. 2002;41(4):378-85. (Pubitemid 38327913)
16. McCarthy S, Cranswick N, Potts L, Taylor E, Wong ICK. Mortality associated with attention deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the General Practice Research Database. Drug Saf. 2009;32(11):1089-96.
17. Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA. 2011;306(24):2673-83.
18. Anderson GD. Pregnancy-induced changes in pharmacokinetics. Clin Pharmacokinet. 2005;44(10):989-1008.
19. Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs. 1995;50(2):222-39.
20. Petrenaite V, Sabers A, Hansen-Schwartz J. Individual changes in lamotrigine plasma concentrations during pregnancy. Epilepsy Res. 2005;65(3):185-8. (Pubitemid 41187572)
21. Ohman I, Vitols S, Tomson T. Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation. Epilepsia. 2000;41(6):709-13. (Pubitemid 30390423)
22. Golub M, Costa L, Crofton K, Frank D, Fried P, Gladen B, et al. NTP CERHR Expert Panel report on the reproductive and developmental toxicity of methylphenidate. Birth Defects Res B Dev Reprod Toxicol. 2005;74(4):300-81. (Pubitemid 41267328)
23. Dideriksen D, Pottegard A, Hallas J, Aagaard L, Damkier P. First trimester in utero exposure to methylphenidate. Basic Clin Pharmacol Toxicol. 2013;112(2):73-6.
24. Pottegard A, Hallas J, Andersen JT, Lokkegaard EC, Dideriksen D, Aagaard L, et al. First-trimester exposure to methylphenidate: a population-based cohort study. J Clin Psychiatry. 2014;75(1):e88-93.
25. Kopelman AE, McCullar FW, Heggeness L. Limb malformations following maternal use of haloperidol. J Am Med Assoc. 1975;231(1):62-4.
26. Lundquest DE, Young WK, Edland JF. Maternal death associated with intravenous methylphenidate (Ritalin) and pentazocine (Talwin) abuse. J Forensic Sci. 1987;32(3):798-801. (Pubitemid 17103477)
27. Debooy VD, Seshia MM, Tenenbein M, Casiro OG. Intravenous pentazocine and methylphenidate abuse during pregnancy. Maternal lifestyle and infant outcome. Am J Dis Child. 1993;147(10):1062-5. (Pubitemid 23298094)
28. Bolea-Alamanac BM, Green A, Verma G, Maxwell P, Davies SJ. Methylphenidate use in pregnancy and lactation: a systematic review of evidence. Br J Clin Pharmacol. 2014;77(1):96-101.
29. Humphreys C, Garcia-Bournissen F, Ito S, Koren G. Exposure to attention deficit hyperactivity disorder medications during pregnancy. Can Fam Physician. 2007;53(7):1153-5. (Pubitemid 47235998)
30. Plessinger MA. Prenatal exposure to amphetamines. Risks and adverse outcomes in pregnancy. Obstet Gynecol Clin North Am. 1998;25(1):119-38. (Pubitemid 28141704)
31. Oei JL, Kingsbury A, Dhawan A, Burns L, Feller JM, Clews S, et al. Amphetamines, the pregnant woman and her children: a review. J Perinatol. 2012;32(10):737-47.
32. Elliott L, Loomis D, Lottritz L, Slotnick RN, Oki E, Todd R. Case-control study of a gastroschisis cluster in Nevada. Arch Pediatr Adolesc Med. 2009;163(11):1000-6.
33. Eriksson M, Jonsson B, Zetterstrom R. Children of mothers abusing amphetamine: head circumference during infancy and psychosocial development until 14 years of age. Acta Paediatr. 2000;89(12):1474-8. (Pubitemid 32044191)
34. Naeye RL. Maternal use of dextroamphetamine and growth of the fetus. Pharmacology. 1983;26(2):117-20. (Pubitemid 13174585)
35. Milkovich L, van der Berg BJ. Effects of antenatal exposure to anorectic drugs. Am J Obstet Gynecol. 1977;129(6):637-42. (Pubitemid 8241383)
36. Stiefel G, Besag FM. Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder. Drug Saf. 2010;33(10):821-42.
37. Jones J, Rios R, Jones M, Lewis D, Plate C. Determination of amphetamine and methamphetamine in umbilical cord using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877(29):3701-6.
38. Joya X, Pujadas M, Falcon M, Civit E, Garcia-Algar O, Vall O, et al. Gas chromatography-mass spectrometry assay for the simultaneous quantification of drugs of abuse in human placenta at 12th week of gestation. Forensic Sci Int. 2010;196(1-3):38-42.
39. Eriksson M, Larsson G, Winbladh B, Zetterstrom R. The influence of amphetamine addiction on pregnancy and the newborn infant. Acta Paediatr Scand. 1978;67(1):95-9. (Pubitemid 8277817)
40. American Academy of Pediatrics. Breastfeeding and the use of human milk: policy statement. American Academy of Pediatrics (2014). http://pediatrics. aappublications.org/content/129/3/e827.full.
41. Heinig MJ, Dewey KG. Health advantages of breastfeeding for infants: a critical review. Nutr Res Rev. 1996;9(1):89-110. (Pubitemid 126493264)
42. Mimouni-Bloch A, Kachevanskaya A, Mimouni FB, Shuper A, Raveh E, Linder N. Breastfeeding may protect from developing attention-deficit/hyperactivity disorder. Breastfeed Med. 2013;8(4):363-7.
43. Ilett KF, Hackett LP, Kristensen JH, Kohan R. Transfer of dexamphetamine into breast milk during treatment for attention deficit hyperactivity disorder. Br J Clin Pharmacol. 2007;63(3):371-5.
44. Spigset O, Brede WR, Zahlsen K. Excretion of methylphenidate in breast milk. Am J Psychiatry. 2007;164(2):348.
45. Hackett LP, Ilett KF, Kristensen JH, Kohan R, Hale TW. Infant dose and safety of breastfeeding for dexamphetamine and methylphenidate in mothers with attention deficit hyperactivity disorder: 40. Ther Drug Monit. 2005;27(2):220-1.
46. Milberger S, Biederman J, Faraone SV, Guite J, Tsuang MT. Pregnancy, delivery and infancy complications and attention deficit hyperactivity disorder: issues of gene-environment interaction. Biol Psychiatry. 1997 Jan 1;41(1):65-75. (Pubitemid 27050647)
47. Kiblawi ZN, Smith LM, LaGasse LL, Derauf C, Newman E, Shah R, et al. The effect of prenatal methamphetamine exposure on attention as assessed by continuous performance tests: results from the Infant Development, Environment, and Lifestyle study. J Dev Behav Pediatr. 2013;34(1):31-7.
48. LaGasse LL, Derauf C, Smith LM, Newman E, Shah R, Neal C et al. Prenatal methamphetamine exposure and childhood behavior problems at 3 and 5 years of age. NTP-CERHR monograph on the potential human reproductive and developmental effects of amphetamines. Pediatrics. 2012 Apr;129(4):681-8.
49. O'Connor TG, Heron J, Golding J, Beveridge M, Glover V. Maternal antenatal anxiety and children's behavioural/emotional problems at 4 years: report from the Avon Longitudinal Study of Parents and Children. Br J Psychiatry. 2002;180(6):502-8. (Pubitemid 34596800)
50. de La Rochebrochard E, Joshi H. Children born after unplanned pregnancies and cognitive development at 3 years: social differentials in the United Kingdom Millennium Cohort. Am J Epidemiol. 2013;178(6):910-20.